Salvage Treatment and the Role of Transplantation in Lymphomas

1. Kuruvil­la J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009; 497– 506. doi: 10.1182/ asheducation‑ 2009.1.497.

2. Schmitz N, Pfistner B, Sextro M et. al. Aggres­sive conventional chemotherapy compared with high‑dose chemotherapy with autologous haemopoietic stem‑ cel­l transplantation for relapsed chemosensitive Hodgkin‘s disease: a randomised trial. Lancet 2002; 359(9323): 2065– 2071.

3. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone‑ mar­row transplantation in relapsed and resistant Hodgkin‘s disease: results of a BNLI randomised trial. Lancet 1993; 341(8852): 1051– 1054.

4. Jost­ing A, Ruef­fer U, Franklin J et al. Prognostic factors and treatment outcome in primary progres­sive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96(4): 1280– 1286.

5. Jost­ing A, Mul­ler H, Brochman­n P et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin‘s lymphoma. J Clin Oncol 2010; 28(34): 5074– 5080. doi: 10.1200/ JCO.2010.30.5771.

6. Kuruvil­la J, Keat­ing A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011; 117(16): 4208– 4217. doi: 10.1182/ blood‑ 2010‑ 09‑ 288373.

7. Jabbour E. Hos­ing C, Ayers G et al. Pretransplant positive positron emis­sion tomography/ gal­lium scans predict poor outcome in patients with recur­rent/ refractory Hodgkin lymphoma. Cancer 2007; 109(12): 2481– 2489.

8. Moskowitz AJ, Yahalom J, Kewalramani T et al. Pretransplantation functional imag­ing predicts outcome fol­low­ing autologous stem cel­l transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116(23): 4934– 4947. doi: 10.1182/ blood‑ 2010‑ 05‑ 282756.

9. Reece DE, Barnett MJ, Con­nors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide fol­lowed by autologous bone mar­row transplantation for relapsed Hodgkin‘s disease. J Clin Oncol 1991; 9(10): 1871– 1879.

10. Visani G, MalerbaL, Stefani PM et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cel­l transplantation is safe and ef­fective for resistant/ relapsed lymphoma patients. Blood 2001; 118(12): 3419– 3425. doi: 10.1182/ blood‑ 2011‑ 04‑ 351924.

11. Fung HC, Stif­f P, Schriber J et al. Tandem autologous stem cel­l transplantation for patients with primary refractory or poor risk recur­rent Hodgkin lymphoma. Biol Blood Mar­r Transplant 2007: 13(5): 594– 600.

12. Morschhauser F, Brice P, Fermé C et al. Risk‑adapted salvage treatment with single or tandem autologous stem‑ cel­l transplantation for first relapse/ refractory Hodgkin‘s lymphoma: results of the prospective multicenter H96 trial by the GELA/ SFGM study group. J Clin Oncol 2008; 26(36): 5980– 5897. doi: 10.1200/ JCO.2007.15.5887.

13. Devil­lier R, Coso D, Castagna L et al. Positron emis­sion tomography response at the time of autologous stem cel­l transplantation predicts outcome of patients with relapsed and/ or refractory Hodgkin‘s lymphoma respond­ing to prior salvage therapy. Haematologica 2012; 97(7): 1073– 1079. doi: 10.3324/ haematol.2011.056051.

14. Pohlreich D, Vackova B, Trnkova M et al. Fifty percent cure rate in poor risk relapsed/ refractory Hodgkin lymphoma after tandem autologous stem cel­l transplantation. EBMT 2014: abstr. 2381.

15. Gajewski JL, Phil­lips GL, Sobocinski KA et al. Bone mar­row transplants from HLA‑identical siblings in advanced Hodgkin‘s disease. J Clin Oncol 1996: 14(2): 572– 578.

16. Milpied N, Field­ing AK, Pearce RM et al. Al­logeneic bone mar­row transplant is not better than autologous transplant for patients with relapsed Hodgkin‘s disease. European Group for Blood and Bone Mar­row Transplantation. J Clin Oncol 1996: 14(4): 1291– 1296.

17. Sureda A, Robinson S, Canals C et al. Reduced‑ intensity condition­ing compared with conventional al­logeneic stem‑ cel­l transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lamphoma Work­ing Party of the European Group for Blood and Mar­row Transplantation. J Clin Oncol 2008: 26(3): 455– 462.

18. Robinson SP, Sureda A, Canals C et al. Reduced intensity al­logeneic stem cel­l transplantation for hodgkin’s lymphoma: Identification of prognostic factors predict­ing outcome. Haematol 2009; 94(2): 230– 238. doi: 10.3324/ haematol.13441.

19. Bur­roughs LM, O’Don­nel PV, Sandmaier BM et al. Comparison of outcomes of HLA‑matched related, unrelated, or HLA‑haploidentical related hematopoietic cel­l transplantation fol­low­ing nonmyeloablative condition­ing for relapsed or refractory Hodgkin lymphoma. Biol Blood Mar­row Transplantation 2008; 14(11): 1279– 1287. doi: 10.1016/ j.bbmt.2008.08.014.

20. Peggs KS, Kasvani I, Edwards N et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T‑ cel­l‑ depleted al­logeneic transplantation for Hodgkin’s lymfoma. J Clin Oncol 2011: 29(8): 971– 978. doi: 10.1200/ JCO.2010.32.1711.

21. Coif­fier B, Lepage E, Briere J et al. CHOP like chemotherapy plus rituximabcompared with CHOP alone inelderly patients with dif­fuse large‑ B‑ cel­l lymphoma. N Engl J Med 2002; 346(4): 235– 242.

22. Pfreundschuh M, Trümper L, Ostergorg A et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone inyoung patients with good‑ prognosis dif­fuse large‑ B‑ cel­l lymphoma: a randomized control­led trial by the MabThera International Trial Group. Lancet Oncol 2006; 7(5): 379– 391.

23. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone mar­row transplantation as compared with salvage chemotherapy in relapses of chemotherapy‑ sensitive non‑Hodkin’s lymphoma. N Eng J Med 1995; 333(23): 1540– 1545.

24. Thieblemont C, Briere J, Mounier N et al. The germinal center/ activated B‑ cel­l subclas­sification has a prognostic impact for response to salvage therapy in relapsed/ refractory dif­fuse large B‑ cel­l lymphoma: a bio­‑ CORAL study. J Clin Oncol 2011; 29(31): 4079– 4087. doi: 10.1200/ JCO.2011.35.4423.

25. Gis­selbrecht C, Glas­s B, Mounier N et al. Salvage regiments with autologous transplantation for relapsed large B‑ cel­l lymphomain the rituximab era. J Clin Oncol 2010; 28(27): 4184– 4190. doi: 10.1200/ JCO.2010.28.1618.

26. Crump M, Kuruvil­la J, Couban S et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem‑ cel­l transplantation for relapsed and refractory aggres­sive lymphomas: NCIC‑ CTG LY.12. J Clin Oncol 2014: 32(31): 3490– 3496. doi: 10.1200/ JCO.2013.53.9593.

27. Martín A, Conde E, Arnan M et al. R‑ ESHAP as salvage therapy for patients with relapsed or refractory dif­fuse large B‑ cel­l lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/ TAMO study. Haematologica 2008; 93(12): 1829– 1836. doi: 10.3324/ haematol.13440.

28. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second‑line therapy before autologous stem cel­l transplantation for relapsed or primary refractory dif­fuse large B‑ cel­l lymphoma. An­n Hematol 2007; 86: 107– 115.

29. Vel­lenga E, van Putten WT, van’t Veer MB et al. Rituximab improves the treatment results of DHAP‑ VIM‑ DHAP and ASCTin relapsed/ progres­sive agres­sive CD 20+ NHL: a prospective randomised HOVON trial. Blood 2008; 111(2): 537– 543.

30. Van Kampen RJ, Canals C, Schouten HC et al. Al­logeneic stem‑ cel­l transplantation as salvage therapy for patients with dif­fuse large B‑ cel­l lymphoma Relaps­ing after an autologous stem‑ cel­l transplantation: an analysis of the Euuropean Group for Blood and Mar­row Transplantation registry. J Clin Oncol 2011; 29(10): 1342– 1348. doi: 10.1200/ JCO.2010.30.2596.

31. Freytes CO, Zhang MJ, Car­reras J et al. Outcome of lower‑ intensity al­logeneic transplantation in non‑Hodgkin lymphoma after autologous transplantation failure. Biol Blood Mar­row Transplant 2012; 18(8): 1255– 1264. doi: 10.1016/ j.bbmt.2011.12.581.

32. Sureda A, Bader P, Cesaro S et al. Indications for al­lo‑  and auto‑ SCT for haematological diseases, solid tumours and im­mune disorders: cur­rent practice in Europe, 2015. Bone Mar­r Transpl 2015: 50(8): 1037– 1056. doi: 10.1038/ bmt.2015.6.

33. Al Khabori, de Almeida JR, Guyatt GH et al. Autologous stem cel­l transplantation in fol­licular lymphoma: A systematic review and meta‑analysis. J Natl Cancer Inst 2012; 104(1): 18– 28. doi: 10.1093/ jnci/ djr450.

34. Schouten HC, Qian W, Kvaloy S et al. High‑dose therapy improves progres­sion‑free survival and survival in relapsed fol­licular non‑Hodgkin‘s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21(21): 3918– 3927.

35. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/ or high‑dose therapy with autotransplant at time of relapse in patients with fol­licular lymphoma: a GELA study. J Clin Oncol 2008; 26(21): 3614– 3620. doi: 10.1200/ JCO.2007.15.5358.

36. Kornacker M, Stum­m J, Pott C et al. Characteristics of relapse after autologous stem‑ cel­l transplantation for fol­licular lymphoma: a long‑term fol­low‑up. An­n Oncol 2009; 20(4): 722– 728. doi: 10.1093/ an­nonc/ mdn691.

37. Pettengel­l R, Schmitz N, Gis­selbrecht C et al. Rituximab purg­ing and/ or maintenance in patients undergo­ing autologous transplantation for relapsed fol­licular lymphoma: a prospective randomized trial from the lymphoma work­ing party of the European group for blood and mar­row transplantation. J Clin Oncol 2013; 31(13): 1624– 1630. doi: 10.1200/ JCO.2012.47.1862.

38. Vose J, Armitage J, Weisenburger D et al. International peripheral T‑ cel­l and natural kil­ler/ T‑ cel­l lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26(25): 4124– 4130. doi: 10.1200/ JCO.2008.16.4558.

39. Schmitz N, Trümper L, Ziepert M et al. Treatment and prognosis of mature T‑ cel­l and NK‑ cel­l lymphoma: an analysis of patients with T‑ cel­l lymphoma treated in studies of the German High‑Grade Non‑ Hodgkin Lymphoma Study Group. Blood 2010; 116(18): 3418– 3425. doi: 10.1182/ blood‑ 2010‑ 02‑ 270785.

40. Janikova A, Bortlicek Z, et al. CHOEP versus CHOP gives better results in first‑line therapy of t‑ cel­l lymphoma. A retrospective analysis from czech lymphoma study group (CLSG) database. Hematological Oncology 2015; 33 (Suppl 1): abstr. 99.

41. Cor­radini P, Tarel­la C, Zal­lio F et al. Long‑term fol­low‑up of patients with peripheral T‑ cel­l lymphomas treated up‑ front with high dose chemotherapy fol­lowed by autologous stem cel­l transplantaion. Leukemia 2006; 20(9): 1533– 1538.

42. Rodrigues J, Conde E, Gutiér­rez A et al. Frontline autologous stem cel­l transplantation in high‑risk peripheral T‑ cel­l lymphoma: a prospective study from The Gel‑ Tamo Study Group. Eur J Haematol 2007; 79(1): 32– 38.

43. Reimer P, Rüdiger T, Geis­singer E et al. Autologous stem cel­l transplantation as first‑line therapy in peripheral T‑ cel­l lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27(1): 106– 113. doi: 10.1200/ JCO.2008.17.4870.

44. d‘Amore F, Relander T, Lauritzsen GF et al. Up‑ front autologous stem‑ cel­l transplantation in peripheral T‑ cel­l lymphoma: NLG‑ T‑ 01. J Clin Oncol 2012; 30(25): 3093– 3099. doi: 10.1200/ JCO.2011.40.2719.

45. Rodrigues J, Cabal­lero MD, Gutiér­rez A et al. High‑dose chemotherapy and autologous stem cel­l transplantation in peripheral T‑ cel­l lymphoma: the GEL‑ TAMO experience. An­n Oncol 2003; 14(12): 1768– 1775.

46. Rodrigues J, Conde E, Gutiér­rez A et al. The adujusted International Prognostic Index and beta‑2– microglobulin predict the outcome after autologous stem cel­l transplantation in relapsing/ refraktory peripheral T‑ cel­l lymphoma. Haematologica 2007; 92(8): 1067– 1074.

47. Chen A, McMil­lan A, Negrin RS et al. Long‑term results af autologous hematopoietic cel­l transplantation for peripheral T‑ cel­l lymphoma: the Stanford experience. Biol Blood Mar­row Transplant 2008; 14(7): 741– 747. doi: 10.1016/ j.bbmt.2008.04.004.

48. Kyriakou C, Canals C, Goldstone A et al. High‑dose therapy and autologous stem‑ cel­l transplantation in angioimunoblaststic lymphoma: complete remis­sion at transplantation is the major determinant of outcome –  Lymphoma Work­ing Party of the European Group for Blood and Mar­row Transplantation. J Clin Oncol 2008; 26(2): 218– 224. doi: 10.1200/ JCO.2007.12.6219.

49. Dodero A, Spina F, Narni F et al. Al­logeneic transplantation fol­low­ing a reduced intensity condition­ing regimen in relapsed/ refractory peripheral T‑ cel­l lymphomas: long term remis­sions and response to donor lymphocyte infusions support the role of a graft versus lymphoma ef­fect. Leukemia 2012; 26(3): 520– 526. doi: 10.1038/ leu.2011.240.

50. Valkova V, Benesova K, Vitek A et al. The results of al­logeneic transplants in patients with malignant lymphoma‑ a retrospective analysis of data from the Czech National Registry. Neoplasma 2009; 56(1): 76– 83.

51. Cor­radini P, Vitolo U, Rambaldi A et al. Intensified chemo‑ im­munotherapy with or without stem cel­l transplantation in newly dia­gnosed patients with peripheral T‑ cel­l lymphoma. Leukemia 2014; 28(9): 1885– 1891. doi: 10.1038/ leu.2014.79.

52. Schmitz N, Nickelsen M, Altman­n B et al. Al­logeneic or autologous transplantation as first‑line therapy for younger patients with peripheral T‑ cel­l lymphoma: results of the interim analysis of the AATT trial. J Clin Oncol ASCO Meet­ing Abstracts 2015; 33 (15 Suppl): 8507.